![Gary Swan](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Gary Swan
Director de Operaciones en Laureate Biopharmaceutical Services, Inc. .
Perfil
Gary Swan is currently the Vice President of Operations at Laureate Biopharmaceutical Services, Inc. He previously worked as the Senior Director of Manufacturing at MDRNA, Inc. and as the Vice President of Operations at V.I.
Technologies, Inc. Swan received his undergraduate degree from Auburn University.
Cargos activos de Gary Swan
Empresas | Cargo | Inicio |
---|---|---|
Laureate Biopharmaceutical Services, Inc.
![]() Laureate Biopharmaceutical Services, Inc. Pharmaceuticals: MajorHealth Technology Laureate Biopharmaceutical Services, Inc. provides biopharmaceutical development and protein production services. It offers product development and manufacturing services from cell line optimization and process design to development of full-scale cGMP protein production, purification and aseptic filling, in addition to corresponding testing, validation, analytical and regulatory support. The firm's focus is on mammalian cell based monoclonal antibody and recombinant protein production for clinical and modest commercial supply. The company was founded in 1981 and is headquartered in Princeton, NJ. | Director de Operaciones | - |
Antiguos cargos conocidos de Gary Swan.
Empresas | Cargo | Fin |
---|---|---|
MDRNA, Inc.
![]() MDRNA, Inc. Miscellaneous Commercial ServicesCommercial Services MDRNA, Inc. engages in development and commercialization of innovative products based on proprietary molecular biology-based intranasal drug delivery technology. The company creates or utilizes novel formulation components or excipients that can transiently manipulate or open 'tight junctions' between cells in various tissues and thereby allow therapeutic drugs to reach the blood stream. The company is located in Hauppauge, NY. | Corporate Officer/Principal | - |
V.I. Technologies, Inc.
![]() V.I. Technologies, Inc. BiotechnologyHealth Technology Vitex is a Delaware Corporation incorporated in 1995. Vitex’s scientific and clinical programs originated in anti-infective technologies designed to prevent the spread of infectious disease by blood transfusions. In March of 2005, Vitex merged with Panacos Pharmaceuticals, a private company developing HIV therapeutics with novel mechanisms of action. The merger with Panacos immediately expanded the Vitex pipeline into novel, high value therapeutics. The Panacos team that joined Vitex is recognized for fundamental contributions to HIV biology and drug development | Director de Operaciones | - |
Formación de Gary Swan.
Auburn University | Undergraduate Degree |
Experiencias
Funciones ocupadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas privadas | 3 |
---|---|
Laureate Biopharmaceutical Services, Inc.
![]() Laureate Biopharmaceutical Services, Inc. Pharmaceuticals: MajorHealth Technology Laureate Biopharmaceutical Services, Inc. provides biopharmaceutical development and protein production services. It offers product development and manufacturing services from cell line optimization and process design to development of full-scale cGMP protein production, purification and aseptic filling, in addition to corresponding testing, validation, analytical and regulatory support. The firm's focus is on mammalian cell based monoclonal antibody and recombinant protein production for clinical and modest commercial supply. The company was founded in 1981 and is headquartered in Princeton, NJ. | Health Technology |
V.I. Technologies, Inc.
![]() V.I. Technologies, Inc. BiotechnologyHealth Technology Vitex is a Delaware Corporation incorporated in 1995. Vitex’s scientific and clinical programs originated in anti-infective technologies designed to prevent the spread of infectious disease by blood transfusions. In March of 2005, Vitex merged with Panacos Pharmaceuticals, a private company developing HIV therapeutics with novel mechanisms of action. The merger with Panacos immediately expanded the Vitex pipeline into novel, high value therapeutics. The Panacos team that joined Vitex is recognized for fundamental contributions to HIV biology and drug development | Health Technology |
MDRNA, Inc.
![]() MDRNA, Inc. Miscellaneous Commercial ServicesCommercial Services MDRNA, Inc. engages in development and commercialization of innovative products based on proprietary molecular biology-based intranasal drug delivery technology. The company creates or utilizes novel formulation components or excipients that can transiently manipulate or open 'tight junctions' between cells in various tissues and thereby allow therapeutic drugs to reach the blood stream. The company is located in Hauppauge, NY. | Commercial Services |
- Bolsa de valores
- Insiders
- Gary Swan